Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 118Other hematologic neoplasm 48Genitourinary 35Sarcoma 4Plasma cell 4Gynecologic 4Gastrointestinal 4Breast 4Thoracic 2Tumor-Agnostic 1Dermatologic 1CNS 1

Conditions

Triple Negative Breast Neoplasms 1Thymoma 1Ovarian Neoplasms 1Neoplasms 1Myasthenia Gravis 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Carboplatin 1145Cisplatin 874Pemetrexed 832pembrolizumab 604Paclitaxel 597Docetaxel 535Gemcitabine 424Radiotherapy 374Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 294durvalumab 254Drug Therapy 233osimertinib 217atezolizumab 207Radiosurgery 188Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 123Magnetic Resonance Spectroscopy 120Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Prednisolone × Thoracic × Clear all
NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Eisai Inc.

Phase 1/2 Recruiting
182 enrolled
BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00294658 2017-05-23

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

University of Alabama at Birmingham

Phase 3 Completed
126 enrolled 42 charts
Thoracic

Myasthenia Gravis, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡